AZN · Healthcare · $245.0B
After-hours $158.00+0.19%
What's this stock's score right now?
See its score for free — revenue and money flow, graded on one standard.
Quarterly Financials
9/'26
6/'26 vs prev quarter
Among 19 Drug Manufacturers - General peers
Quarterly Revenue Growth
“종양학 부문이 상반기 +15% 성장하며 전체 매출을 이끌었어요 — 특히 Enhertu +31%, Calquence +16%로 가속됐고, 오늘 발”
In the company's words · 2026 2분기 earnings call